Phase II
It was a particularly busy week for announcements about clinical trials, both related to COVID-19 and everything else. Here’s a look.
The positive findings were shared as part of the company’s Emergency Use Authorization submission for its investigational COVID-19 therapy.
Recent Greenphire data shows new participant enrollment up 85% since slump in April.
Eli Lilly is continuing their other trial in mild-to-moderate COVID-19 patients and stated they “remain confident … that bamlanivimab monotherapy may prevent progression of disease for those earlier in the course of COVID-19.”
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 27, 2020.
Treatment with FORMA Therapeutics’ investigational agent olutasidenib has shown promising efficacy and safety in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and mutations in isocitrate dehydrogenase 1 (IDH1m).
Novartis released promising interim Phase II data of iptacopan in C3 glomerulopathy (C3G). The analysis was presented at the virtual American Society of Nephrology (ASN) 2020 Annual Meeting.
It was another busy week for clinical trial updates and news. Here’s a look.
Finding and developing an effective treatment for nonalcoholic steatohepatitis has, so far, been met with as much futility and frustration as developing a treatment for Alzheimer’s disease. Sagimet Biosciences Chief Executive Officer George Kemble believes his company is on the right path, though.
Biogen originally announced the initiation of its Phase II clinical trial, AFFINITY, designed to evaluate opicinumab back in 2017. The drug was being examined as an investigational add-on therapy for patients with relapsing MS.
PRESS RELEASES